The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells
Open Access
- 13 December 2019
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 80 (3) , 267-273
Abstract
Background: Prostate cancer (PCa) is one of the most frequently diagnosed tumors in men. In general, therapies for localized PCa are curative. However, treatment of advanced PCa is considered palliative since development of therapy resistance occurs rapidly. It has been shown that tumor‐initiating cells are likely involved in therapy resistance. They are not eliminated by conventional therapies and thereby lead to tumor progression and relapse. The aim of this study was to evaluate the effects of the known stem cell inhibitor salinomycin on this critical subpopulation of cells.Methods: Expression of the cell surface markers CD24 and CD44 was assessed by immunofluorescence and fluorescence‐activated cell sorting. Colony formation efficiency and classification of colony types with varying tumor‐initiating potential (holoclones, meroclones, and paraclones) were analyzed in an automated way by the newly developed CATCH‐colonies software in the absence or presence of salinomycin.Results: Automated high‐resolution colony formation analysis consistently identified the various colony types in a broad range of PCa cell lines. Serial clonogenic assays confirmed that holoclones show the highest colony formation potential and maintain their tumor‐initiating capacity over multiple rounds. Furthermore, holoclones showed high expression of CD44, while CD24 was not expressed in these clones, thus representing the well‐described tumor‐initiating CD24−/CD44high population. Salinomycin decreased the CD24−/CD44high population in both docetaxel‐sensitive PC3 and docetaxel‐resistant (DR) PC3‐DR. Moreover, treatment of PC3, DU145, PC3‐DR, and DU145‐DR with salinomycin led to a significant reduction in the colony formation potential by targeting the colonies with high tumor‐initiating potential.Conclusions: Taken together, we demonstrated that salinomycin specifically targets the tumor‐initiating cell population in docetaxel‐sensitive and docetaxel‐resistant PCa cells and may represent a potential therapeutic approach for the treatment of advanced PCa.Keywords
Funding Information
- Austrian Science Fund (W1101‐B12)
This publication has 30 references indexed in Scilit:
- Prostate Luminal Progenitor Cells in Development and CancerTrends in Cancer, 2018
- Syndecan‐1 (CD138) contributes to prostate cancer progression by stabilizing tumour‐initiating cellsThe Journal of Pathology, 2013
- Prostate cancer stem cells: Are they androgen-responsive?Molecular and Cellular Endocrinology, 2012
- Stem Cell Characteristics in Prostate Cancer Cell LinesEuropean Urology, 2010
- PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisMolecular Cancer, 2010
- PC3 Human Prostate Carcinoma Cell Holoclones Contain Self-renewing Tumor-Initiating CellsCancer Research, 2008
- A tumour stem cell hypothesis for the origins of prostate cancerBJU International, 2005
- Retention of Intrinsic Stem Cell Hierarchies in Carcinoma-Derived Cell LinesCancer Research, 2005
- Stem cells, cancer, and cancer stem cellsNature, 2001
- Three clonal types of keratinocyte with different capacities for multiplication.Proceedings of the National Academy of Sciences, 1987